Hematuria Market

Market Overview:

The 7 major hematuria markets are expected to exhibit a CAGR of 2.23% during 2024-2034.

The hematuria market has been comprehensively analyzed in IMARC's new report titled "Hematuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hematuria is a medical term that refers to the presence of red blood cells in the urine. The blood may come from various parts of the urinary tract, like the bladder, ureters, kidneys, or urethra. This condition can mainly be categorized into two types: gross and microscopic. In gross hematuria, blood in the urine is visible to the naked eye, giving the urine a reddish or pinkish color, whereas, in microscopic hematuria, small amounts of blood are detectable only through a microscope during a urine test. Individuals suffering from the ailment might experience a sense of urgency to urinate, lower abdominal pain or discomfort, increased frequency of urination, blood clots, swelling in the legs or feet, etc. The diagnosis of hematuria is typically based on the patient's clinical features, medical history, urinalysis, and several other laboratory tests. A healthcare provider may also perform computed tomography scans and magnetic resonance imaging to visualize detailed cross-sectional pictures of the urinary tract. Depending on the suspected causative factor of the disease, various blood workups, such as kidney function tests, coagulation profiles, and inflammatory markers, may be conducted to confirm the diagnosis among patients.

The increasing prevalence of urinary tract infections that can cause inflammation and irritation, leading to blood in the urine, is primarily driving the hematuria market. In addition to this, the rising cases of blood disorders, in which the body's normal clotting mechanism becomes impaired, resulting in easy bruising and excessive bleeding, are also creating a positive outlook for the market. Moreover, the widespread adoption of shock wave lithotripsy procedures to alleviate the presence of blood in the urine by removing or reducing the size of the kidney stones that might be causing the underlying condition, is further bolstering the market growth. Apart from this, the inflating application of immunosuppressive drugs on account of their numerous advantages, such as controlling autoimmune processes, minimizing renal inflammation, and preventing disease progression, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cystoscopy, which allows direct visualization of the bladder lining, thereby helping to identify the source of bleeding accurately, is expected to drive the hematuria market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hematuria market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hematuria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hematuria market in any manner.

Recent Developments:

• In May 2024, Vera Therapeutics presented data from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), which demonstrated that atacicept stabilized kidney function for 72 weeks and resulted in rapid improvements in hematuria.

Key Highlights:

• The prevalence of hematuria, or blood in the urine, can range substantially from 0.19% to 31.1%.
• Hematuria can be categorized into two kinds based on its duration: transient hematuria and persistent or severe hematuria.
• Hematuria is more common among older people and smokers.
• Hematuria induced by sickle cell disease is more common in Blacks and Hispanics than in whites.
• The male-female hematuria ratio is 0.82:1.2.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hematuria market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hematuria market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hematuria marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
      

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the hematuria market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hematuria market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hematuria market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of hematuria across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hematuria by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hematuria by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with hematuria across the seven major markets?
• What is the size of the hematuria patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hematuria?
• What will be the growth rate of patients across the seven major markets?

Hematuria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hematuria drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hematuria market?
• What are the key regulatory events related to the hematuria market?
• What is the structure of clinical trial landscape by status related to the hematuria market?
• What is the structure of clinical trial landscape by phase related to the hematuria market?
• What is the structure of clinical trial landscape by route of administration related to the hematuria market?